Twenty-four-month data show sustained clinical responses for patients receiving neuroimmune modulation therapy for rheumatoid arthritis (RA), according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.